Other Events ·
Eton launches ET-900 program for epileptic spasms; IND submitted with dosing targeted Q1 2027
ETONEton Pharmaceuticals, Inc.
Eton Pharmaceuticals announced the initiation of ET-900, a new development program evaluating mecasermin injection for infantile and epileptic spasms. The company entered into a license agreement with Baylor College of Medicine covering patent rights related to insulin-like growth factor 1 (IGF-1) for this indication. A research Investigational New Drug application has been submitted to the FDA for an investigator-sponsored Phase 2 clinical study targeting children with refractory epileptic spasms, with initial enrollment and patient dosing expected in the first quarter of 2027. Eton retains commercial rights to the program as it expands into pediatric neurology. The company is an innovative pharmaceutical firm focused on developing and commercializing treatments for rare diseases.